Breast Cancer Research and Treatment

Article	Citations
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	87
Prognostic and predictive impact of NOTCH1 in early breast cancer	85
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	82
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	68
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	68
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	67
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	56
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	56
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	52
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	46
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	44
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	44
Endocrine adherence in male versus female breast cancer: a seer-medicare review	44
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China	41
Area deprivation index and breast cancer outcomes among patients in Western New York	41
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	36
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	36
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	35
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	31
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study	31
Surveillance mammography after treatment for male breast cancer	31
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis	30
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	29
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	29
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	29

Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	29
Integrating SENOMAC and AMAROS: a call for de-escalation	28
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients	28
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	27
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	26
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	26
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	26
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	24
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	24
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	23
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy	23
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	23
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	23
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al	23
Hormone-associated dietary patterns and premenopausal breast cancer risk	22
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk	22
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms	22
Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception	22
Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis	22
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study	22
Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies	21
Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations	21
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?	21
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021	21
Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019	21
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients	21
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry	20
Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer	20
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a media	20
Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study	20
A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients	20
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study	19
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer	19
Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study	19
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study	19
Clinical trials of immunotherapy in triple-negative breast cancer	19
A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer	19
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent ki	19
Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene	18
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy	18
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis	18
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings	18
Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients	18
Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management	18
Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea	18
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study	18
Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis	18
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer	18
Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan	17
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma	17

A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial	17
Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017	17
Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer	17
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial	17
A mixed method study of medical oncologists’ perceived barriers and motivators to addressing long-term effects in breast cancer survivors	17
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study	17
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy	17
Omission of multimodal therapy in older adults with high-risk breast cancer	17
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263	17
Male breast cancer: a multicenter study to provide a guide for proper management	17
Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population	17
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer regist	17
Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma	16
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review	16
Multi-omics portrait of ductal carcinoma in situ in young women	16
Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis	16
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis	16
Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases	16
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study	16
Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer	16
Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients	16
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status	16
A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells	16
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients	16
Strict definition of a small tumor in breast cancer should be revisited	16
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?	16
Clinical and sociodemographic determinants of older breast cancer survivors’ reports of receiving advice about exercise	16
HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles	15
Correlation analysis between shear-wave elastography and pathological profiles in breast cancer	15
Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort	15
Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study	15
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study	15
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer	15
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice	15
Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort	15
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world	15
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany	15
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction	15
Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer	15
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)	15
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer	14
Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)	14
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis	14
Influence of rurality on lymph node assessment among women diagnosed with ductal carcinoma in situ and treated with mastectomy, SEER 2000–2015	14
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer	14
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium	14
Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	14
Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention	14
Letter to the editor regarding “Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany”	14
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer	14
Multi-level factors drive use of sentinel lymph node biopsy in older women with early-stage breast cancer	14
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy—results of the multicenter UMBRELLA breast cancer cohort	14
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases	14
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer	14
Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy	13
Changes in the survival of patients with breast cancer: Poland, 2000–2019	13
Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins	13
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities	13
Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital	13
Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study	13
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis	13
Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database	13
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial	13
Organoid models derived from patients with malignant phyllodes tumor of the breast	13
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer	13
PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer	13
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials	13
Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and	13
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit	13
High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors	13
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study	13
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center	13
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer	12
Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy	12
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey	12
Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting	12
Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data	12
Association of body composition and surgical outcomes in patients with early-stage breast cancer	12
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative br	12
A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast	12

Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016	12
Correction: The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection	12
Diagnostic performance of screening mammography according to menstrual cycle among Asian women	12
Estimating the incidence of breast cancer recurrence using administrative data	12
Limitations of locoregional and distant recurrence analysis after neoadjuvant chemotherapy	12
Lumpectomy surgery for large ductal carcinoma in situ	12
The importance of SOCS1 − 1478 CA/del polymorphism and expression in breast cancer: a case–control study in the north of Iran	12
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer	12
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast)	12
An overview of genetic services delivery for hereditary breast cancer	12
Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study	12
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer	12
Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics	12
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age	12
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis	12
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases	12
Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis	12
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors	12
Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer	12
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer	12
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study	12
Reply to: “Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)”	12
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome	11
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients	11
Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study	11
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction	11
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease	11
Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study	11
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers	11
Perceptions of breast cancer risk after breast density notification in a population-based screening program	11
Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis	11
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review	11
Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer	11
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41	11
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study	11
Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors	11
Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review	11
Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis	11
Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis	11
Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression	11
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark	11
High-resolution microCT to assess breast microcalcification morphometry by histologic lesion subtype and radiologic classification	11
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy	11
Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review	11
BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses	11
Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique	11
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey	11
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi	11
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project	11
Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression	11
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy	11
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study	11
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series	11
Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis	11
Long-term benefits of exercise interventions during chemotherapy in breast cancer: insights from the optitrain trial calling for longitudinal studies	10
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study	10
History of infertility and risk of breast cancer: a prospective cohort study	10
First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer	10
Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long Non-coding RNA in Breast Cancer Metastasis	10
Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?	10
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry	10
Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center	10
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?	10
Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ	10
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, car	10
The association between age at breast cancer diagnosis and prevalence of pathogenic variants	10
Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study	10
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer	10
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-	10
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)	10
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors	10
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer	10
Oral minoxidil for late alopecia in cancer survivors	10
Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide c	10
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study	10
Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment	10
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy	10
Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer	10
Reply to Bourgeois P.	10
Molecular characterization of ESR1 variants in breast cancer	10
Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques	10
Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study	10
Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer	10
Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery	9
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study	9
Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients	9
Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy	9
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor	9
Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer	9
Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer	9
Time and location of specialty palliative care for women dying with metastatic breast cancer	9
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study	9
Cardiotoxicity among socioeconomically marginalized breast cancer patients	9
Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evalua	9
Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer	9